Protalix (PLX +5.5%) signs an agreement with Pfizer (PFE) in which the latter will conduct and...

|About: Protalix BioTherapeutics,... (PLX)|By:, SA News Editor

Protalix (PLX +5.5%) signs an agreement with Pfizer (PFE) in which the latter will conduct and sponsor new trials for Protalix's Elelyso treatment for Gaucher disease, which stops cells and organs from working properly. Protalix will be eligible to receive milestone payments of up $8.3M; the company will continue to conduct existing trials of Elelyso. (PR)